Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Rheumatology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Rheumatology Articles

Tuesday 4th October, 2005

 

The FDA approved HUMIRA® (adalimumab) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

 
 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version
 

  Related
 
  Adalimumab plus methotrexate effective for rheumatoid arthritis  
   

Abbott Park, Illinois ? Abbott announced that the U.S. Food & Drug Administration (FDA) approved HUMIRA? (adalimumab) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis, a chronic disease that combines the symptoms of arthritis, including joint pain and inflammation, with those of psoriatic skin disease, such as dry, scaly skin.

Psoriatic arthritis (PsA) is a serious autoimmune disease and few available treatment options address the potentially devastating combination of symptoms affecting both the skin and joints. Psoriatic arthritis is the first new disease indication for HUMIRA beyond rheumatoid arthritis (RA) and is one of the five autoimmune diseases Abbott is studying for HUMIRA therapy.

"The pain of psoriatic arthritis combined with the social stigma of its visible symptoms places a huge burden on people living with this disease," said Gail M. Zimmerman, president and chief executive officer of the National Psoriasis Foundation. "The symptoms can be debilitating and some patients experience diminished quality of life that may leave them feeling depressed and socially isolated. The HUMIRA approval brings another effective treatment option and hope for patients with this potentially devastating disease."

HUMIRA in Psoriatic Arthritis

The HUMIRA approval is based on results of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), which is the largest biologic trial in PsA. ADEPT studied 313 adult patients with moderately to severely active PsA who had an inadequate response to NSAID (non-steroidal anti-inflammatory drug) therapy. HUMIRA patients experienced significantly greater improvement in both joint and skin disease symptoms than placebo-treated patients at 24 weeks. Improvements in both skin lesions and joint symptoms were seen as early as two weeks after initiation of treatment and continued to improve over time.

Patients' arthritic symptoms also responded to HUMIRA, with nearly 60 percent of patients achieving ACR20 at week 12, one of the study's primary endpoints, and with a sustained response through week 24. ACR70, a more stringent response criterion, was achieved by nearly 25 percent of patients treated with HUMIRA vs. 1 percent of patients treated with placebo at week 24. American College of Rheumatology (ACR) scores measure the percentage of improvement in tender and swollen joint count and several other clinical measures.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


"Clinical improvement in arthritic symptoms that can lead to disability as well as the pain and stiffness that keeps patients from functioning normally was rapid and significant with HUMIRA," said rheumatologist Philip Mease, M.D., Swedish Medical Center and University of Washington School of Medicine, Seattle, and lead investigator of the ADEPT study.

Clinical trial data from ADEPT showed the ability of HUMIRA to improve both the skin and joint symptoms associated with psoriatic arthritis. Among the 69 patients in the trial who had skin lesions involving greater than 3 percent body surface area (the palm of an adult hand represents approximately 1 percent of the body?s skin surface) who were treated with HUMIRA, three out of four achieved PASI 50 (75 percent), three out of five achieved a PASI 75 (59 percent) and two out of five (42 percent) achieved a PASI 90 response at 24 weeks, which reflects at least 50, 75 or 90 percent improvement in skin symptoms assessed by the Psoriasis Area and Severity Index (PASI).

The skin symptoms of psoriatic arthritis can severely affect patients' day-to-day lives," said dermatologist Kenneth Gordon, M.D., incoming co-director of Dermatology, Evanston Northwestern Healthcare. "The approval of HUMIRA gives patients access to a medication that can significantly impact skin symptoms and allow them to engage in everyday activities again, such as shaking hands when closing a business deal or going to a public pool."

After taking HUMIRA, my skin improved for the first time in years," said Annie Escalona, a native of Seattle and hiking enthusiast. "My joint pain kept getting better and my skin was much clearer. I can now wear a backpack, swim and enjoy activities I would have never dreamed of doing just a few years ago."

The recommended dose of HUMIRA for psoriatic arthritis is 40 mg every-other-week by subcutaneous injection (a shot beneath the skin), the usual dose used for HUMIRA in the treatment of moderate to severe RA.

The rates of adverse events and serious adverse events in the ADEPT trial were comparable with other HUMIRA RA clinical trials. Among patients taking HUMIRA, the most common adverse events (those affecting at least 5 percent of patients) were upper respiratory infection, nasopharyngitis, injection site reaction, headache and hypertension. The safety profile of HUMIRA in the ADEPT clinical trial was similar to that observed in the HUMIRA RA clinical trials.

Abbott simultaneously submitted applications with the FDA and the European Medicines Agency seeking approval to market HUMIRA to treat psoriatic arthritis and early moderate to severe RA in December 2004. Abbott also announced today FDA approval for HUMIRA for early RA and received European approval for psoriatic arthritis and early severe RA on August 8, 2005.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2012 DoctorsLounge®. All rights reserved.